Palabras clave
Colombia
COVID-19
Vacunas
Cómo citar
Resumen
En octubre 31 del 2021, Colombia inició la vacunación contra COVID-19 para niños de 3 a 11 años de edad, con
la vacuna CoronaVac (Sinovac). Esta estrategia se implementó en ausencia de un informe técnico sobre la eficacia
y seguridad de CoronaVac en niños, y sin una evaluación del costo-beneficio de esta, en comparación con otras
estrategias. En este comentario se consideran aspectos fundamentales que debieron tomarse en cuenta al ponderar si
los beneficios de esta estrategia eran mayores que sus riesgos. Específicamente, la eficacia y seguridad de CoronaVac
en niños de 3 a 11 años, la relación riesgo/beneficio de la estrategia, el rol de los niños en la transmisión comunitaria
de SARS-CoV-2, y las implicaciones éticas de la estrategia.
Referencias
Palacios R, Batista AP, Albuquerque CSN, González Patiño E, do Prado Santos J, Reis Pessoa Conde MT, et al. Efficacy and safety of a COVID-19 inactivated vaccine in healthcare professionals in Brazil: the PROFISCOV study. 2021. doi: https://dx.doi.org/10.2139/ssrn.3822780
Tanriover MD, Doğanay HL, Akova M, Güner HR, Azap A, Akhan S, et al. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebocontrolled, phase 3 trial in Turkey. Lancet. 2021; 398(10296): 213-222. doi: https://doi.org/10.1016/S0140-6736(21)01429-X
Bueno SM, Abarca K, González PA, Gálves N, Soto JA, Duarte L, et al. Interim report: Safety and immunogenicity of an inactivated vaccine against SARS-CoV-2 in healthy chilean adults in a phase 3 clinical trial. BMJ 2021; 374. doi: https://doi.org/10.1136/bmj.n2015
Ranzani OT, Hitchings M, Dorion M, Lang D’Agostini T, Cardoso de Paula R, Ferreira Pereira de Paula O, et al. Effectiveness of the CoronaVac vaccine in the elderly population during a P.1 variant-associated epidemic of COVID-19 in Brazil: A test-negative case-control study. medRxiv. 2021:2021.2005.2019.21257472. doi: 10.1136/bmj.n2015
Jara A, Undurraga EA, González C, Paredes F, Fontecilla T, Jara G, et al. Effectiveness of an Inactivated SARSCoV-2 Vaccine in Chile. N Engl J Med. 2021; 385(10): 875-884. doi: https://doi.org/10.1056/NEJMoa2107715
Arregoces L, Fernández J, Rojas-Botero M, Palacios-Calvijo AF, Galvis M, Rincón LE, et al. Effectiveness of COVID-19 vaccines in preventing hospitalizations and deaths in Colombia: A pair-matched, national-wide cohort study in older adults. SSRN. 2021. doi: https://dx.doi.org/10.2139/ssrn.3944059
Han B, Song Y, Li C, Yang W, Ma Q, Jiang Z, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2021; 21(12) 1645-1653. doi: https://doi.org/10.1016/S1473-3099(21)00319-4
Callaway E. COVID vaccines and kids: five questions as trials begin. Nature. 2021; 592(7856): 670-671. doi: https://doi.org/10.1038/d41586-021-01061-4
Ministerio_de_Salud_Chile. Informe Estadístico: ESAVI de Vacuna de SARS-CoV-2 (CoronaVac) notificados en niños entre 6 y 11 años de edad, (Periodo13 septiembre - 7 octubre 2021). In: Instituto_de_Salud_Pública, ed. Santiago, Chile: Ministerio de Salud; 2021. https://www.ispch.gob.cl/wp-content/uploads/2021/10/20211021-Informe-estadistico-ESAVI-ninos-6-y-11-anos-VFinal.pdf
SINOVAC. COVID-19 Vaccine (Vero cell), Inactivated AEFI Analysis Report among the Population Aged 3-17 Years Beijing, China: SINOVAC; 2021.
Dyer O. Covid-19: US and China prepare for mass vaccination of children under 12. BMJ. 2021; 375: n2631. doi: https://doi.org/10.1136/bmj.n2631
Zheng W, Yan X, Zhao Z, Yang J, Yu H. COVID-19 vaccination program in the mainland of China: a subnational descriptive analysis on target population size and current progress. Infectious diseases of poverty. 2021; 10(1):1-10. doi: https://doi.org/10.1186/s40249-021-00909-1
Khera N, Santesmasses D, Kerepesi C, Gladyshev VN. COVID-19 mortality rate in children is U-shaped. Aging (Milano). 2021; 13(16): 19954-19962. doi: https://doi.org/10.18632/aging.203442
Santesmasses D, Castro JP, Zenin AA, Shindyapina A, Gerashchenko MV, Zhang, B, et al. COVID-19 is an emergent disease of aging. Aging Cell. 2020/10/01 2020; 19(10): e13230. doi: https://doi.org/10.1111/acel.13230
Hillis SD, Unwin HJT, Chen Y, Cluver L, Sherr L, Goldman PS, et al. Global minimum estimates of children affected by COVID-19-associated orphanhood and deaths of caregivers: a modelling study. Lancet. 2021; 398(10298): 391-402. doi: https://doi.org/10.1016/S0140-6736(21)01253-8
Madewell ZJ, Yang Y, Longini IM, Halloran ME, Dean NE. Household transmission of SARS-CoV-2: a systematic review and meta-analysis. JAMA Netw Open. 2020; 3(12): e2031756. doi: 10.1001/jamanetworkopen.2020.31756
Shah K, Saxena D, Mavalankar D. Secondary attack rate of COVID-19 in household contacts: a systematic review. QJM. 2020; 113(12): 841-850. doi: 10.1093/qjmed/hcaa232
Rosledzana MA, Alikhan MF, Jamaludin SA, et al. What do we know about SARS-CoV-2 transmission? A systematic review and meta-analysis of the secondary attack rate and associated risk factors. PLoS One. 2020; 15(10): e0240205. doi: https://doi.org/10.1371/journal.pone.0240205
Ludvigsson JF. Children are unlikely to be the main drivers of the COVID‐19 pandemic–a systematic review. Acta Paediatr. 2020; 109(8): 1525-1530. doi: https://doi.org/10.1111/apa.15371
Irfan O, Li J, Tang K, Wang Z, Bhutta ZA. Risk of infection and transmission of SARS-CoV-2 among children and adolescents in households, communities and educational settings: A systematic review and meta-analysis. J Glob Health. 2021; 11. doi: https://dx.doi.org/10.7189%2Fjogh.11.05013
Goldstein E, Lipsitch M, Cevik M. On the effect of age on the transmission of SARS-CoV-2 in households, schools, and the community. J Infect Dis. 2021; 223(3): 362-369. doi: 10.1093/infdis/jiaa691
Madewell ZJ, Yang Y, Longini IM, Halloran ME, Dean NE. Factors Associated With Household Transmission of SARS-CoV-2: An Updated Systematic Review and Meta-analysis. JAMA Netw Open. 2021; 4(8): e2122240. doi: 10.1001/jamanetworkopen.2021.22240
Thompson HA, Mousa A, Dighe A, Fu A, Arnedo-Peña A, Barrett P, et al. Severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) setting-specific transmission rates: A systematic review and meta-analysis. Clin Infect Dis. 2021; 73(3): e754-e764. doi: https://doi.org/10.1093/cid/ciab100
Walsh KA, Spillane S, Comber L, Cardwell K, Harrington P, Connell J, et al. The duration of infectiousness of individuals infected with SARS-CoV-2. J Infect. 2020; 81(6): 847-856. doi: 10.1016/j.jinf.2020.10.009
Viner RM, Mytton OT, Bonell C, et al. Susceptibility to SARS-CoV-2 Infection Among Children and Adolescents Compared With Adults: A Systematic Review and Meta-analysis. JAMA Pediatrics. 2021; 175(2): 143-156. doi: https://doi.org/10.1001/jamapediatrics.2020.4573
Walsh S, Chowdhury A, Braithwaite V, Russell S, Birch J, Ward J. Do school closures and school reopenings affect community transmission of COVID-19. A systematic review of observational studies. medRxiv. 2021. doi: http://dx.doi.org/10.1136/bmjopen-2021-053371
Xu W, Li X, Dozier M, He Y, Kirolos A, Lang Z, et al. What is the evidence for transmission of COVID-19 by children in schools? A living systematic review. J Glob Health. 2020; 10(2): 021104. doi: 10.7189/jogh.10.021104
Viner RM, Russell SJ, Croker H, Packer J, Ward J, Stansfield C, et al. School closure and management practices during coronavirus outbreaks including COVID-19: a rapid systematic review. The Lancet Child & Adolescent Health. 2020; 4(5): 397-404. doi: https://doi.org/10.1016/S2352-4642(20)30095-X
World Health Organization. Interim statement on COVID-19 vaccination for children and adolescents. 2021. Disponible en: https://www.who.int/news/item/24-11-2021-interim-statement-on-covid-19-vaccination-forchildren-and-adolescents
Ministerio de Salud y Protección Social. Resolución 1738 Por la cual se modifican los Anexos Técnicos 1, 2 y 7 de la Resolución 1151 de 2021, en relación con la vacunación de población pediátrica con el biológico Coronavac de Sinovac Life Sciences Co., Ltd, contra el Covid-19. Bogotá DC; 2021. Disponible en: https://www.minsalud.gov.co/Normatividad_Nuevo/Resoluci%C3%B3n%20No.%201738%20de%202021.pdf#:~:text=MINISTERIO%20DE%20SALUD%20Y%20PROTECCI%C3%93N%20SOCIAL%20RESOLUCI%C3%93N%20N%C3%9AMERO,pandemia%20y%20la%20evidencia%20cient%C3%ADfica%20sobre%20la%20vacuna
Esta obra está bajo una licencia internacional Creative Commons Atribución 4.0.
Derechos de autor 2021 Leonelo E. Bautista, Laura A. Rodríguez-Villamizar, Víctor M. Herrera-Galindo, Ruth A. Martínez-Vega, Luis M. Sosa-Ávila, Myriam Oróstegui Arenas, Lina M. Vera-Cala, Jorge L. Alvarado-Socarrás, Alvaro J. Idrovo